FDA Adverse Event Other Summary report: N

RADIESSE DERMAL FILLER

MDR report key: 4102766 · Received September 9, 2014

Report

Report Number
2135225-2014-00058
Event Type
Other
Date Received
September 9, 2014
Date of Event
August 1, 2014
Report Date
August 18, 2014
Manufacturer
MERZ NORTH AMERICA
Product Code
LMH
PMA / PMN Number
P050052
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
VA, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

ON (B)(6) 2014, (B)(6) STATED THE "PATIENT IS 100 PERCENT BETTER". THE PATIENT HAS A VERY SMALL DISCOLORATION "BUBBLE" ON THE SIDE OF HER NOSE THAT'S HEALING WELL. THE DEVICE HISTORY RECORD FOR RADIESSE LOT 100071730 WAS REVIEW. ALL REQUIRED TESTING SPECIFICATIONS FOR THIS LOT WERE MET PRIOR TO RELEASE. NO NON-CONFORMANCES WERE DISCOVERED THAT WOULD HAVE CONTRIBUTED TO THIS EVENT.

Description of Event or Problem · 1

THIS SPONTANEOUS REPORT WAS RECEIVED FROM A PHYSICIAN VIA A COMPANY EMPLOYEE AND CONCERNS A (B)(6) FEMALE INJECTED WITH TWO 1.5 CC RADIESSE INTO NASOLABIAL FOLDS, INFRA-ORBITAL RIM AND PRE-JOWL ON (B)(6) 2014. THE PATIENT EXPERIENCED FACIAL SWELLING AND PAIN WITHIN 24 HOURS. SHE WAS SENT TO THE EMERGENCY ROOM (ER) ON AUGUST 7, 2014 AND TO AN INFECTIOUS DISEASES PHYSICIAN FOR A DIAGNOSIS OF INFECTION. THE PATIENT RECEIVED INTRAVENOUS ANTIBIOTICS, FROM EITHER ER PHYSICIAN OR THE INFECTIOUS DISEASES PHYSICIAN; NAME, DOSE, FREQUENCY AND DURATION WERE NOT REPORTED. ON (B)(6) 2014, DR. (B)(4) SPOKE WITH DR. (B)(6) REGARDING HIS PATIENT. THE PATIENT THAT DR. (B)(6) TREATED FOR (B)(6) HAS A CLEAR VASCULAR OCCLUSION. DURING THE FOLLOW-UP CONVERSATION, DR. (B)(6) WILL REVIEW THE WAY TO DIAGNOSE A VASCULAR OCCLUSION AND HOW TO TREAT IT. IN ADDITION, TECHNIQUES WILL BE DISCUSSED ON HOW TO AVOID SUCH AN EVENT IN THE FUTURE. NO ADDITIONAL INFORMATION WAS PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
556391 RADIESSE DERMAL FILLER INJECTABLE IMPLANT LMH MERZ NORTH AMERICA 100071730

Patients

Seq Age Sex Outcome Treatment
1 66 YR